IA
RCKT icon

IFP Advisors’s Rocket Pharmaceuticals RCKT Stock Holding History

IFP Advisors’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.22K Buy
1,818
+274
+18% +$911 ﹤0.01% 3652
2026
Q1 		$5.53K Buy
1,544
+1,218
+374% +$4.84K ﹤0.01% 3458
2025
Q4 		$1.14K Sell
326
-317
-49% -$1.08K ﹤0.01% 4029
2025
Q3 		$2.1K Sell
643
-39
-6% -$123 ﹤0.01% 3676
2025
Q2 		$1.67K Buy
682
+498
+271% +$2.52K ﹤0.01% 3979
2025
Q1 		$1.23K Buy
184
+170
+1,214% +$1.68K ﹤0.01% 3291
2024
Q4 		$176 Buy
+14
New +$211 ﹤0.01% 3805
2023
Q4 		– Sell
-25
Closed -$512 – 3279
2023
Q3 		$512 Hold
25
– – ﹤0.01% 3105
2023
Q2 		$497 Hold
25
– – ﹤0.01% 3196
2023
Q1 		$496 Hold
25
– – ﹤0.01% 3184
2022
Q4 		$1K Buy
25
+5
+25% +$92 ﹤0.01% 4454
2022
Q3 		$1K Buy
+20
New +$312 ﹤0.01% 4656
2021
Q2 		– Sell
-15
Closed -$651 – 3200
2021
Q1 		$0 Sell
15
-1
-6% -$55 ﹤0.01% 3187
2020
Q4 		$0 Buy
+16
New +$583 ﹤0.01% 3068

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

IFP Advisors's RCKT Position: Q2 2026 in Review

IFP Advisors increased its Rocket Pharmaceuticals (RCKT) stake by 18% in Q2 2026, buying an estimated $911 and bringing the position to 1,818 shares worth $6.22K. The position accounts for ﹤0.01% of the portfolio, ranked #3652.

IFP Advisors first reported a position in RCKT in Q4 2020 and has held it in 14 quarters since. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • IFP Advisors held 1,818 shares of Rocket Pharmaceuticals worth $6.22K as of Q2 2026.
  • IFP Advisors bought 274 Rocket Pharmaceuticals shares in Q2 2026, an estimated $911.
  • Rocket Pharmaceuticals made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #3652 holding.
  • IFP Advisors first reported a position in Rocket Pharmaceuticals in Q4 2020 and has held it in 14 quarters since.
  • 180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.